VWM
ADMA icon

Vermillion Wealth Management’s ADMA Biologics ADMA Stock Holding History

Vermillion Wealth Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12
Closed -$108 – 1541
2026
Q1 		$108 Buy
+12
New +$189 ﹤0.01% 1426

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vermillion Wealth Management's ADMA Position: Q2 2026 in Review

Vermillion Wealth Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 12 shares — an estimated $108 sold.

Vermillion Wealth Management first reported a position in ADMA in Q1 2026 and held it in 1 quarter. The position peaked at $108 in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Vermillion Wealth Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 12 ADMA Biologics shares in Q2 2026, an estimated $108.
  • Vermillion Wealth Management first reported a position in ADMA Biologics in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's ADMA Biologics position peaked at $108 in Q1 2026.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.